DrugWipe

DrugWipe is a portable drug-residue and drug-screening test associated with Securetec. The product is designed for rapid, on-site screening rather than laboratory confirmation. Its moist collection wipe can be used to sample drug traces from surfaces, or biological material from locations such as the forehead, palm, or tongue. Depending on the configuration, the test can also analyze saliva or sweat from an individual. The collected material is transferred through an integrated ampoule into an immunoassay area, where antibodies on test strips bind to compounds or metabolites associated with selected drug classes. DrugWipe configurations have been described as capable of screening for cannabis, cocaine, opiates, amphetamines, MDMA, and benzodiazepines. The product category is particularly relevant to roadside enforcement, probation, workplace screening, and other situations in which authorities or operators need a preliminary result without immediately sending a specimen to a laboratory. A saliva-focused version, DrugWipe 6S, was entered in the Traffic Enforcement category of the 2011 Cygnus Law Enforcement Group Innovation Awards and was named a finalist. The product’s principal value proposition is speed, portability, and the ability to screen directly at the point of contact. Its limitations are typical of rapid immunoassay screening but have been especially debated in connection with cannabis detection. Independent field research has reported substantial false-negative rates for cannabis, while other evaluations have found that performance varies by drug class and testing conditions. Oral-fluid testing also involves smaller sample volumes than urine testing, and drug concentrations in saliva may differ considerably from those in blood or urine. Consequently, a positive or negative DrugWipe result should not automatically be treated as equivalent to a laboratory-confirmed finding. Research involving Finnish police use reported that many positive roadside results for cannabis, cocaine, and opioids did not agree with blood-test results. The Finnish Parliamentary Ombudsman criticized the practice of using such results as sufficient grounds for driving bans. Separate roadside research in Switzerland found that DrugWipe identified substantially fewer exposed drivers than parallel gas-chromatography/mass-spectrometry testing in one cannabis-focused comparison. Other comparative testing found that several oral-fluid screening devices detected roughly 70 percent of cocaine and cannabis users in a roadside setting, while amphetamine and MDMA detection was higher. These findings illustrate both the practical usefulness and the evidentiary limits of the product. DrugWipe has also been cited as effective for screening certain difficult or altered drug samples, including so-called black cocaine in a U.S. Drug Enforcement Administration bulletin. Overall, DrugWipe is best understood as a field screening brand in forensic, law-enforcement, and occupational-testing contexts, with confirmatory laboratory analysis remaining important when results carry legal or medical consequences. Publicly available reference material does not establish the brand’s founding date, corporate ownership structure, headquarters, current distribution footprint, or present operating status.

DrugWipe emerged as a field-oriented drug screening product built around a moist sampling wipe and antibody-based immunoassay strips. Rather than requiring a conventional laboratory workflow, the device is intended to collect material and produce a preliminary indication at the point where a person, vehicle, or surface is being examined. The design supports several sampling contexts: drug residue can be collected from surfaces, while sweat or saliva can be sampled from an individual. An internal ampoule releases the transport medium that moves the collected analyte to the antibody-binding region of the test. The product family has been configured to screen for several drug classes, including cannabis, cocaine, opiates, amphetamines, MDMA, and benzodiazepines. This multi-analyte capability made the device relevant to police and other professional users who need a compact screening tool rather than a single-substance laboratory assay. A saliva-only configuration known as DrugWipe 6S received public recognition when it became a finalist in the Traffic Enforcement category of the 2011 Cygnus Law Enforcement Group Innovation Awards. DrugWipe’s history has also been shaped by scrutiny of analytical performance. Independent testing has repeatedly emphasized that rapid oral-fluid immunoassays are not interchangeable with confirmatory blood, urine, or gas-chromatography/mass-spectrometry analysis. Cannabis has been a particular challenge. Finnish field testing reported low sensitivity and a high proportion of results that did not correspond with blood samples. The Finnish Parliamentary Ombudsman objected to treating roadside screening results as adequate by themselves for imposing driving bans. A Swiss roadside comparison similarly found that the device identified only one exposed driver while parallel laboratory analysis identified eighteen positive drivers in the tested group. Such findings do not eliminate the product’s role as a preliminary screen, but they show why confirmatory testing and interpretation of cutoffs are important. Comparative roadside research has reported uneven performance by drug class. Several tested oral-fluid devices, including DrugWipe, detected about 70 percent of cocaine and cannabis users in one setting, while amphetamine and MDMA users were detected at rates above 92 percent. The results were affected by collection volume, analyte concentration, device cutoffs, and the short period during which some drugs remain detectable in saliva. In a separate context, a U.S. Drug Enforcement Administration bulletin cited DrugWipe’s ability to detect black cocaine even where some chemical tests did not identify the substance. Available reference material does not provide a reliable founding date, founder, headquarters, corporate history, ownership structure, or complete account of current commercial operations. The documented record instead centers on the product’s testing mechanism, law-enforcement applications, award recognition, and the evidentiary debate surrounding rapid roadside screening.

1. 2011DrugWipe 6S becomes an innovation-award finalist

   The saliva-only DrugWipe 6S was listed as a finalist in the Traffic Enforcement category of the Cygnus Law Enforcement Group Innovation Awards.

   Source

Rapid, portable, on-site drug screening for law-enforcement, roadside, forensic, probation, and related professional applications.

• DrugWipePortable drug screening device

  The core DrugWipe format uses a moist wipe to collect drug residue from a surface or biological material from an individual. An integrated ampoule transfers the sample toward immunoassay strips containing antibodies for selected drug classes. Configurations have been described for cannabis, cocaine, opiates, amphetamines, MDMA, and benzodiazepines. It is intended for rapid field screening and does not replace laboratory confirmation.

• DrugWipe 6SSaliva drug-screening test

  DrugWipe 6S is a saliva-only version of the product family. It was positioned for rapid roadside and traffic-enforcement screening and was entered in the Traffic Enforcement category of the 2011 Cygnus Law Enforcement Group Innovation Awards. Public reference material does not establish its launch date, current availability, or complete analyte configuration.

• 2011DrugWipe 6S named a finalist in the 2011 Cygnus Law Enforcement Group Innovation Awards

  The saliva-only DrugWipe 6S was entered in the Traffic Enforcement category and selected as a finalist in the law-enforcement innovation competition.

  Other
  Source
• Finnish evaluations raised concerns about the reliability of DrugWipe saliva screening

  Reports concerning Finnish police use described high disagreement between positive DrugWipe results and blood-test findings for cannabis, cocaine, and opioids. The controversy contributed to criticism from the Finnish Parliamentary Ombudsman regarding the use of screening results as sufficient grounds for driving bans.

  RegulationOther
  Source

1. Drugwipe test